| abstract |
The disclosure features compositions and methods for treating a metabolic disorder associated with calcitonin gene-related peptide (CGRP), including diabetes, conditions associated with inhibition of insulin secretion, or for increasing longevity. Specifically, the methods comprise administering to a subject suffering a metabolic disorder a therapeutically effective amount of an anti-CGRP antagonist antibody. |